Home » Stocks » RGNX

REGENXBIO Inc. (RGNX)

Stock Price: $40.27 USD 0.34 (0.85%)
Updated Mar 8, 2021 12:57 PM EST - Market open
Market Cap 1.70B
Revenue (ttm) 154.57M
Net Income (ttm) -111.25M
Shares Out 37.28M
EPS (ttm) -2.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $40.27
Previous Close $39.93
Change ($) 0.34
Change (%) 0.85%
Day's Open 39.93
Day's Range 39.01 - 40.82
Day's Volume 99,208
52-Week Range 20.03 - 50.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 6 days ago

Regenxbio (RGNX) delivered earnings and revenue surprises of -211.71% and -83.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 6 days ago

Shares of Regenxbio (NASDAQ:RGNX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 72.22% over the past year to ($1.24), which miss...

PRNewsWire - 6 days ago

ROCKVILLE, Md., March 1, 2021 /PRNewswire/ -- Pivotal program for subretinal delivery of RGX-314 for the treatment of wet AMD is active and enrolling patients; expected to support BLA filing i...

PRNewsWire - 1 week ago

ROCKVILLE, Md., Feb. 24, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following March investor conferences, which will each be held in a virtua...

Zacks Investment Research - 2 weeks ago

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benzinga - 2 weeks ago

Regenxbio Inc (NASDAQ: RGNX) has reported additional interim data from Cohorts 4 and 5 of its Phase 1/2a trial evaluating RGX-314 for the treatment of wet age-related macular degeneration (wet...

PRNewsWire - 2 weeks ago

ROCKVILLE, Md., Feb. 16, 2021 /PRNewswire/ -- RGX-314 using subretinal delivery continues to be generally well-tolerated at all dose levels Positive interim update from Cohorts 4 and 5 at 1.5 ...

PRNewsWire - 3 weeks ago

ROCKVILLE, Md., Feb. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that additional positive interim data from a total of eight patients in Cohorts 1 and 2 of the ongoin...

PRNewsWire - 1 month ago

ROCKVILLE, Md., Feb. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that two oral presentations will be presented at the Angiogenesis, Exudation, and Degeneration 2021 c...

PRNewsWire - 1 month ago

ROCKVILLE, Md., Feb. 1, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and nine poster presentations will be presented at the 17th Annual WORLDSymposium™, t...

PRNewsWire - 1 month ago

ROCKVILLE, Md., Jan. 12, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced underwritten public offering of 4,260,000 shares of its comm...

PRNewsWire - 1 month ago

ROCKVILLE, Md., Jan. 11, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 a...

PRNewsWire - 2 months ago

ROCKVILLE, Md., Jan. 8, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 4,260,000 shares of its common stock at the price o...

Investors Business Daily - 2 months ago

Regenxbio launched a key study of its eye disease-targeting gene therapy, prompting RGNX stock to pop on Wednesday. It's also planning to test a gene therapy in muscular dystrophy.

PRNewsWire - 2 months ago

ROCKVILLE, Md., Jan. 6, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therap...

Zacks Investment Research - 2 months ago

REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy

The Motley Fool - 2 months ago

These three small-cap stocks all turned a profit last quarter and present ample growth potential at bargain prices.

Other stocks mentioned: KOP, ZYXI
PRNewsWire - 2 months ago

ROCKVILLE, Md., Jan. 5, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on the RGX-314 programs, including the announcement that the pivotal program for RGX-314 for...

PRNewsWire - 2 months ago

ROCKVILLE, Md., Dec. 22, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene ther...

Seeking Alpha - 2 months ago

Back in 2019, the Zolgensma approval validated Regenxbio's NAV technology platform for gene delivery. Despite a slow start, Zolgensma recently hit $1B in cumulative sales. Regenxbio's organic ...

Zacks Investment Research - 2 months ago

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

Other stocks mentioned: BMRN, DCPH, QURE
PRNewsWire - 2 months ago

ROCKVILLE, Md., Dec. 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene ther...

PRNewsWire - 2 months ago

ROCKVILLE, Md., Dec. 8, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene thera...

PRNewsWire - 3 months ago

ROCKVILLE, Md., Dec. 1, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene thera...

PRNewsWire - 3 months ago

ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene ther...

Seeking Alpha - 4 months ago

REGENXBIO, Inc. (RGNX) CEO Ken Mills on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Regenxbio (RGNX) delivered earnings and revenue surprises of 125.84% and 284.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 4 months ago

Shares of Regenxbio (NASDAQ:RGNX) were flat after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 124.47% over the past year to $0.23, whic...

PRNewsWire - 4 months ago

ROCKVILLE, Md., Oct. 28, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene ther...

InvestorPlace - 4 months ago

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

Other stocks mentioned: CBPO, GLPG, HRTX, ILMN, IONS, LGND
Forbes - 5 months ago

Gene therapy - which aims to treat diseases by essentially inserting a gene into a patient’s cells rather than via drugs or surgery - was a hot trend in the biotech space, but investor interes...

Other stocks mentioned: QURE, SRPT, VYGR
PRNewsWire - 5 months ago

ROCKVILLE, Md., Sept. 30, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene the...

PRNewsWire - 5 months ago

ROCKVILLE, Md., Sept. 25, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene the...

PRNewsWire - 5 months ago

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduci...

Seeking Alpha - 5 months ago

Regenxbio: More Robust Data For Wet AMD

Other stocks mentioned: AMD
PRNewsWire - 5 months ago

ROCKVILLE, Md., Sept. 9, 2020 /PRNewswire/ -- REGENXBIO Inc.

PRNewsWire - 6 months ago

ROCKVILLE, Md., Aug. 25, 2020 /PRNewswire/ -- REGENXBIO Inc.

Seeking Alpha - 7 months ago

REGENXBIO's (RGNX) CEO Ken Mills on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Regenxbio (RGNX) delivered earnings and revenue surprises of -2.25% and -14.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 7 months ago

ROCKVILLE, Md., Aug. 6, 2020 /PRNewswire/ -- REGENXBIO Inc.

PRNewsWire - 7 months ago

ROCKVILLE, Md., Aug. 4, 2020 /PRNewswire/ -- Company on track to initiate RGX-314 subretinal delivery pivotal program by the end of 2020 RGX-314 was generally well-tolerated in 42 patients at ...

PRNewsWire - 7 months ago

ROCKVILLE, Md., July 30, 2020 /PRNewswire/ -- REGENXBIO Inc.

Zacks Investment Research - 7 months ago

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 8 months ago

ROCKVILLE, Md., July 8, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene thera...

PRNewsWire - 8 months ago

ROCKVILLE, Md., June 10, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene thera...

24/7 Wall Street - 9 months ago

With the COVID-19 pandemic being the biggest health care story in years, it is no surprise that investors and traders have been closely watching and have been doing analysis on the top compani...

Other stocks mentioned: BDX, BDXA, BSX, OHI
Seeking Alpha - 9 months ago

The Wet AMD Gene Therapy Race - Adverum Biotechnologies Vs. Regenxbio

Other stocks mentioned: ADVM
Forbes - 9 months ago

Companies that have been able to deliver compelling results have been acquired by big pharma companies (for instance, Spark Therapeutics was acquired by Roche), while others have underperforme...

Other stocks mentioned: QURE, SRPT
Seeking Alpha - 10 months ago

REGENXBIO, Inc. (RGNX) CEO Kenneth Mills on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About RGNX

REGENXBIO, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is als... [Read more...]

Industry
Biotechnology
IPO Date
Sep 17, 2015
CEO
Kenneth Mills
Employees
257
Stock Exchange
NASDAQ
Ticker Symbol
RGNX
Full Company Profile

Financial Performance

In 2020, REGENXBIO Inc.'s revenue was $154.57 million, an increase of 338.70% compared to the previous year's $35.23 million. Losses were -$111.25 million, 17.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for REGENXBIO Inc. stock is "Buy." The 12-month stock price forecast is 63.78, which is an increase of 58.38% from the latest price.

Price Target
$63.78
(58.38% upside)
Analyst Consensus: Buy